{"qas": [{"question": "Who put out a report in 2012?", "id": "571acf6232177014007e9f1c", "answers": [{"text": "President's Council of Advisors on Science and Technology", "answer_start": 272}], "is_impossible": false}, {"question": "What has been argued restricted innovation?", "id": "571acf6232177014007e9f1d", "answers": [{"text": "excessive regulation", "answer_start": 24}], "is_impossible": false}, {"question": "What was a recommendations brought about from the report?", "id": "571acf6232177014007e9f1e", "answers": [{"text": "expanding the FDA's use of accelerated approval processes", "answer_start": 430}], "is_impossible": false}, {"question": "What is one thing excessive regulations causes?", "id": "571acf6232177014007e9f1f", "answers": [{"text": "therapeutic innovation", "answer_start": 56}], "is_impossible": false}, {"question": "What can be used to evaluate new approval processes?", "id": "571acf6232177014007e9f20", "answers": [{"text": "pilot projects", "answer_start": 610}], "is_impossible": false}, {"question": "What is excessive drug regulation said to suppress?", "id": "571d3d015efbb31900334eda", "answers": [{"text": "therapeutic innovation", "answer_start": 56}], "is_impossible": false}, {"question": "In what year was a report made to reduce the burdens of drug development?", "id": "571d3d015efbb31900334edb", "answers": [{"text": "2012", "answer_start": 253}], "is_impossible": false}, {"question": "What was argued to be holding back new knowledge for treating diseases?", "id": "571d3d015efbb31900334edc", "answers": [{"text": "current cost of regulator-required clinical trials", "answer_start": 93}], "is_impossible": false}, {"plausible_answers": [{"text": "President's Council of Advisors on Science and Technology", "answer_start": 272}], "question": "Who put out a report in 2011?", "id": "5ad3adf5604f3c001a3fec29", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "excessive regulation", "answer_start": 24}], "question": "What has been argued restricted population?", "id": "5ad3adf5604f3c001a3fec2a", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "expanding the FDA's use of accelerated approval processes", "answer_start": 430}], "question": "What was a recommendation brought about from human disease?", "id": "5ad3adf5604f3c001a3fec2b", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "therapeutic innovation", "answer_start": 56}], "question": "What is one thing excessive development causes?", "id": "5ad3adf5604f3c001a3fec2c", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "pilot projects", "answer_start": 610}], "question": "What can be used to evaluate new human diseases?", "id": "5ad3adf5604f3c001a3fec2d", "answers": [], "is_impossible": true}], "context": "Nh\u1eefng ng\u01b0\u1eddi kh\u00e1c \u0111\u00e3 l\u1eadp lu\u1eadn r\u1eb1ng <a1_0><b9_0> quy \u0111\u1ecbnh qu\u00e1 m\u1ee9c <b9_0/><a1_0/> ng\u0103n ch\u1eb7n <a3_0><a5_0><b11_0> c\u1ea3i ti\u1ebfn \u0111i\u1ec1u tr\u1ecb <b11_0/><a5_0/><a3_0/> v\u00e0 r\u1eb1ng <a7_0> chi ph\u00ed hi\u1ec7n t\u1ea1i c\u1ee7a c\u00e1c th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng c\u1ea7n \u0111i\u1ec1u ch\u1ec9nh <a7_0/> ng\u0103n ch\u1eb7n vi\u1ec7c khai th\u00e1c \u0111\u1ea7y \u0111\u1ee7 ki\u1ebfn \u200b\u200bth\u1ee9c v\u1ec1 di truy\u1ec1n v\u00e0 sinh h\u1ecdc m\u1edbi \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb b\u1ec7nh cho ng\u01b0\u1eddi. A <a6_0> 2012 <a6_0/> b\u00e1o c\u00e1o b\u1edfi <a0_0><b8_0> H\u1ed9i \u0111\u1ed3ng c\u1ed1 v\u1ea5n khoa h\u1ecdc v\u00e0 c\u00f4ng ngh\u1ec7 c\u1ee7a T\u1ed5ng th\u1ed1ng <b8_0/><a0_0/> \u0111\u01b0a ra m\u1ed9t s\u1ed1 khuy\u1ebfn ngh\u1ecb ch\u00ednh \u0111\u1ec3 gi\u1ea3m g\u00e1nh n\u1eb7ng ph\u00e1p l\u00fd \u0111\u1ed1i v\u1edbi ph\u00e1t tri\u1ec3n thu\u1ed1c m\u1edbi, bao g\u1ed3m 1) <a2_0><b10_0> m\u1edf r\u1ed9ng vi\u1ec7c s\u1eed d\u1ee5ng quy tr\u00ecnh ph\u00ea duy\u1ec7t t\u0103ng t\u1ed1c c\u1ee7a FDA <b10_0/><a2_0/> , 2) t\u1ea1o ra m\u1ed9t l\u1ed9 tr\u00ecnh ph\u00ea duy\u1ec7t nhanh cho c\u00e1c lo\u1ea1i thu\u1ed1c d\u00e0nh cho s\u1eed d\u1ee5ng trong c\u00e1c qu\u1ea7n th\u1ec3 \u0111\u01b0\u1ee3c x\u00e1c \u0111\u1ecbnh h\u1eb9p v\u00e0 3) th\u1ef1c hi\u1ec7n <a4_0><b12_0> d\u1ef1 \u00e1n th\u00ed \u0111i\u1ec3m <b12_0/><a4_0/> \u0111\u01b0\u1ee3c thi\u1ebft k\u1ebf \u0111\u1ec3 \u0111\u00e1nh gi\u00e1 t\u00ednh kh\u1ea3 thi c\u1ee7a quy tr\u00ecnh ph\u00ea duy\u1ec7t thu\u1ed1c th\u00edch \u1ee9ng m\u1edbi."}